Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Early Phase 1

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06233474Phase 1Active Not Recruiting

Study of Intra-articular Allocetra in Knee Osteoarthritis

Role: lead

NCT06522035Phase 1Terminated

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Role: lead

NCT06208241Early Phase 1Active Not Recruiting

Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety

Role: collaborator

NCT04612413Phase 2Completed

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Role: lead

NCT04922957Phase 2Terminated

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)

Role: lead

NCT04659304Phase 1Unknown

Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

Role: lead

NCT03925857Phase 1Completed

Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS

Role: lead

All 7 trials loaded